Quantcast

Latest Putamen Stories

2011-02-03 08:00:00

SAN DIEGO, Feb. 3, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

2010-11-11 06:00:00

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it has closed its Series D preferred financing in the amount of $11.5 million.

2010-10-19 16:49:41

An international collaboration led by academics at the University of Sheffield, has shed new light into Parkinson´s disease, which could help with the development of cures or treatments in the future.

2010-10-19 11:26:00

SAN DIEGO, Oct. 19 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients.

2010-06-22 11:30:00

SAN DIEGO, June 22 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120.

2010-04-28 06:00:00

SAN DIEGO, April 28 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients.

2010-04-19 15:42:36

Integrated functional network could explain some mysteries of Parkinson's and dystonia

2010-01-20 14:46:38

Researchers can predict your performance on a video game simply by measuring the volume of specific structures in your brain, a multi-institutional team reports this week.

2009-08-05 08:00:00

SAN DIEGO, Aug. 5 /PRNewswire/ -- Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease.

2009-05-27 06:00:00

-- Longer term follow-up indicates modest efficacy in primary and related endpoints -- SAN DIEGO, May 27 /PRNewswire/ -- Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease.


Word of the Day
megalophonous
  • Having a loud voice; vociferous; clamorous.
  • Of grand or imposing sound.
The word 'megalophonous' comes from Greek roots meaning 'big' and 'sound'.